The E3 ubiquitin ligase MAEA promotes macrophage phagocytosis and inhibits gastrointestinal cancer progression by mediating PARP1 ubiquitination and degradation

被引：0
作者：
Feng, Yanchun [2 ]
Zou, Xiangcai [1 ]
Huang, Jintuan [3 ]
Huang, Zhenze [4 ]
Kuang, Guanghao [1 ]
Jiang, Yingming [1 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 2, Dept Thyroid & Hernia Surg, Guangzhou 511436, Guangdong, Peoples R China
[2] Southern Med Univ, Zhujiang Hosp, Microbiome Med Ctr, Dept Lab Med, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gen Surg, Sect 2, Guangzhou 510655, Guangdong, Peoples R China
[4] Southern Med Univ, Zhujiang Hosp, Gen Surg Ctr, Dept Thyroid Surg, Guangzhou, Guangdong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2025年 / 21卷 / 04期
关键词：
MAEA; Gastrointestinal cancer; PARP1; Macrophage; Phagocytosis; DRUG-RESISTANCE; MUTATION; OVARIAN;
D O I：
10.7150/ijbs.102796
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Background: While a role for the E3 ubiquitin ligase MAEA (macrophage erythroblast attacher) has been reported in several cancer types, its importance and mechanistic functions in gastrointestinal cancer (GIC) have yet to be established. Methods: The functions of MAEA in GIC were explored through in vitro and in vivo experiments, including loss- and gain-of-function analyses. Mass spectrometry was used to identify proteins that interact with MAEA. The mechanisms through which MAEA influences tumor aggression were examined through immunoprecipitation analyses. Results: GIC patients exhibiting reduced expression of MAEA were found to exhibit worse disease-free and overall survival outcomes. MAEA was found to impair the proliferation and chemoresistance of GIC tumors in vitro and in subcutaneous xenograft model systems. The combination of MAEA and the PARP1 inhibitor veliparib resulted in enhanced oxaliplatin treatment efficacy in vivo. From a mechanistic perspective, MAEA was found to mediate the K48-linked ubiquitination and degradation of PARP1, in addition to suppressing the M2 polarization of macrophages and enhancing macrophage phagocytic activity. Conclusions: These data suggest that MAEA offers value as a prognostic biomarker and target for the treatment of GIC owing to its ability to degrade PARP1 and augment the phagocytic activity of macrophages.
引用
收藏
页码：1784 / 1800
页数：17
相关论文
共 35 条
  • [1] Siegel RL, Miller KD, Jemal A., Cancer statistics, 2020, CA Cancer J Clin, 70, 1, pp. 7-30, (2020)
  • [2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 6, pp. 394-424, (2018)
  • [3] Rawla P, Sunkara T, Gaduputi V., Epidemiology of pancreatic cancer: Global trends, etiology and risk factors, World J Oncol, 10, 1, pp. 10-27, (2019)
  • [4] Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Et al., Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study, J Clin Oncol, 33, 35, pp. 4176-4187, (2015)
  • [5] Gottesman MM., Mechanisms of cancer drug resistance, Annu Rev Med, 53, pp. 615-627, (2002)
  • [6] Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG., Cancer drug resistance: an evolving paradigm, Nat Rev Cancer, 13, 10, pp. 714-726, (2013)
  • [7] Vasan N, Baselga J, Hyman DM., A view on drug resistance in cancer, Nature, 575, 7782, pp. 299-309, (2019)
  • [8] Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J., Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer, Nat Rev Cancer, 17, 2, pp. 79-92, (2017)
  • [9] Ame JC, Spenlehauer C, de Murcia G., The PARP superfamily, Bioessays, 26, 8, pp. 882-893, (2004)
  • [10] Curtin NJ, Szabo C., Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond, Mol Aspects Med, 34, 6, pp. 1217-1256, (2013)
1234